Skip to Content

About Us

We are advancing potential
therapies to improve the
futures of people living
with devastating
neuromuscular and
neurological disorders

A clinical stage biotech company, PepGen is advancing a new generation of oligonucleotide therapies capable, for the first time, of potentially transforming clinical outcomes for individuals with neuromuscular and neurological disorders.

We are doing this by leveraging our Enhanced Delivery Oligonucleotide (EDO) platform to solve the delivery challenges associated with previous generations of therapies and, achieve deep tissue penetration and high uptake to key muscle tissues.

We have a bold goal, and we won’t stop until we reach it

We are committed to developing truly transformative therapies that create clinically meaningful outcomes to individuals with neuromuscular and neurological diseases including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), and ultimately, to expand into additional indications.

Team

Together we can solve the most difficult challenges and create a new future

We are scientists, physicians, advocates and biotech industry leaders. We bring expertise across scientific, medical, and business disciplines.

But our superpower is our commitment to changing the future.

Executive Team

JAMES MCARTHUR, PHD

President and Chief Executive Officer

LEARN MORE JAMES MCARTHUR, PHD

MARY BETH DELENA

General Counsel and Secretary

LEARN MORE MARY BETH DELENA

NOEL DONNELLY, MBA

Chief Financial Officer

LEARN MORE NOEL DONNELLY, MBA

MICHELLE MELLION, MD

Chief Medical Officer

LEARN MORE MICHELLE MELLION, MD

DAVE BORAH, CFA

Senior Vice President, Investor Relations and Corporate Communications

LEARN MORE DAVE BORAH, CFA

AFSANEH MOHEBBI, PHD

Senior Vice President, Portfolio and Program Management

LEARN MORE AFSANEH MOHEBBI, PHD

HAYLEY PARKER, PHD

Senior Vice President, Global Regulatory Affairs

LEARN MORE HAYLEY PARKER, PHD

NIELS SVENSTRUP, PHD

Senior Vice President Chemistry, Manufacturing and Controls

LEARN MORE NIELS SVENSTRUP, PHD

Senior Leadership

KYLE BREIDENSTINE

Vice President, Finance & Controller

LEARN MORE KYLE BREIDENSTINE

EMIKO BRYANT

Chief of Staff

LEARN MORE EMIKO BRYANT

JEFFREY FOY, PHD

Vice President, Toxicology

LEARN MORE JEFFREY FOY, PHD

EVAN HECKER

Vice President, CMC

LEARN MORE EVAN HECKER

JANE LARKINDALE, DPHIL

Vice President, Clinical Science

LEARN MORE JANE LARKINDALE, DPHIL

PALLAVI LONKAR, PHD

Vice President, Bioanalytical, Biomarkers, and DMPK

LEARN MORE PALLAVI LONKAR, PHD

DEBRA SAWYER

Vice President, Quality Assurance

LEARN MORE DEBRA SAWYER

Board Of Directors

  • JAMES MCARTHUR, PHD

    President and Chief Executive Officer

    LEARN MORE
  • LAURIE KEATING, JD

    Board Chair

    LEARN MORE
  • JOSH RESNICK, MD, MBA

    Non-Executive Director

    LEARN MORE
  • HEIDI HENSON

    Non-Executive Director

    LEARN MORE
  • CHRIS ASHTON, PHD

    Non-Executive Director

    LEARN MORE
  • HABIB JOSEPH DABLE

    Non-Executive Director

    LEARN MORE
  • HOWARD MAYER, MD

    Non-Executive Director

    LEARN MORE

Scientific Advisors

  • MATTHEW WOOD, PHD, MD

    Professor of Neuroscience, Oxford University

    LEARN MORE
  • BRENDA WONG, MD

    Founding Director, UMass Duchenne Program

    LEARN MORE
  • JONATHAN WATTS, PHD

    Professor, UMass Medical School

    LEARN MORE
  • CHARLES THORNTON, MD

    Professor of Neurology & Neuroscience, U Rochester Medical Center

    LEARN MORE
  • BETH MCNALLY, MD

    Director, Center for Genetic Medicine, Northwestern University

    LEARN MORE
  • ART KRIEG, MD

    Former President of the Oligonucleotide Therapeutics Society

    LEARN MORE
  • MICHAEL GAIT, PHD

    Founder

    LEARN MORE
  • JOHN W. DAY, MD, PHD

    Professor of Neurology, Pediatrics (Genetics) and Pathology, Stanford University

    LEARN MORE